(Press-News.org) A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.
The drug is in fact a combination of a chemotherapeutic agent with an antibody, technically called an antibody-drug conjugate (ADC). Just as cells of the immune system use antibodies to recognize pathogens, researchers in this study designed antibodies to recognize a protein over-expressed by these cancer cells, namely the protein mesothelin. The engineered antibodies attach to mesothelin on the cells, and thus bring along their chemotherapeutic cargo directly to the mesothelin-rich cancer cells.
"The deal is that the cell has to express the protein. The more it's expressed only on cancer cells, the more targeted the therapy becomes," says Colin Weekes, MD, PhD, CU Cancer Center investigator and assistant professor in the Division of Oncology at the CU School of Medicine.
A similar antibody-drug conjugate approach is used by the breast cancer agent T-DM1, which attaches chemotherapy to an antibody that seeks the HER2 protein in HER2+ breast cancers.
The current phase I clinical trial, sponsored by the agent's manufacturer, Genentech, was carried out at the University of Colorado Cancer Center, in the Netherlands, and at three Mayo Clinic locations in Scottsdale, Arizona, Jacksonville, Florida, and Rochester Minnesota. The study enrolled 71 patients, with no dose-limiting toxicities seen at maximum study dosage.
"For tumors that overexpress a specific protein ADCs may make sense," Weekes says. "But for other tumors with specific genetic abnormality that doesn't result in overexpression of a protein, it won't make sense."
Additionally, Weekes explains, the creation of antibody-drug conjugates requires technically sophisticated procedures to create "linker constructs" between drug and antibody.
"You can't just put any drug on these things," Weekes says.
But in tumors that overexpress certain proteins, or perhaps in tumors that can be made to overexpress certain proteins, the strategy of targeting cancers with antibody-drug conjugates remains promising. The agent DMOT4039A is now being evaluated for further human trials.
INFORMATION:
Clinical Trials number NCT01469793
Phase I study of DMOT4039A in patients with pancreatic or ovarian cancer
2014-05-30
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Genetic profile predicts which bladder cancer patients will benefit from early chemotherapy
2014-05-30
CHICAGO, IL (May 30, 2014)—Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.
During the study, 36 patients with muscle-invasive bladder cancer received chemotherapy before surgery, consisting of an accelerated regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC). By the time surgery rolled around, 14 patients appeared cancer-free. ...
For the first time in the lab, researchers see stem cells take key step toward development
2014-05-30
CHAMPAIGN, Ill. — The gap between stem cell research and regenerative medicine just became a lot narrower, thanks to a new technique that coaxes stem cells, with potential to become any tissue type, to take the first step to specialization. It is the first time this critical step has been demonstrated in a laboratory.
University of Illinois researchers, in collaboration with scientists at Notre Dame University and the Huazhong University of Science and Technology in China, published their results in the journal Nature Communications.
"Everybody knows that for an embryo ...
Trial uncovers potential dangers of chemotherapy regimen for bladder cancer patients
2014-05-30
CHICAGO, IL (May 30, 2014)—Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs.
All of the 31 patients included in the study received a combination of gemcitabine and cisplatin, two drugs normally administered for 12 weeks before surgery to remove the tumors. This became the standard of care after one study looked back, ...
Atomic structure of essential circadian clock protein complex determined
2014-05-30
Structural biologists have made important progress towards better understanding the functioning of the circadian clock. The circadian or inner clock coordinates the sleep-wake rhythm and many other body processes that regulate, for example, metabolism, blood pressure, and the immune system. A research team led by Professor Eva Wolf, recently appointed Professor of Structural Biology at the Institute of General Botany of Johannes Gutenberg University Mainz (JGU) and Adjunct Director at the Institute of Molecular Biology (IMB), has for the first time identified the molecular ...
Coaxing iPS cells to become more specialized prior to transplantation cuts rejection risk
2014-05-30
STANFORD, Calif. — For many scientists, the clinical promise of stem cells has been dampened by very real concerns that the immune system will reject the transplanted cells before they could render any long-term benefit. Previous research in mice has suggested that even stem cells produced from the subject's own tissue, called iPS cells, can trigger an immune attack.
Now researchers at the Stanford University School of Medicine have found that coaxing iPS cells in the laboratory to become more-specialized progeny cells (a cellular process called differentiation) before ...
Standard approaches to menopause symptoms discount non-Western experiences
2014-05-30
Dr Mwenza T. Blell of the University of Bristol interviewed 257 British Pakistani women aged 39-61 living in West Yorkshire and found that the standard checklist approach to studying menopause symptoms, which ignores women's understanding of their own experience, leaves researchers and clinicians with gaps in their knowledge of the 'true' symptoms of menopause.
Many previous studies into the menopause have relied on standardised checklists, such as the Blatt-Kupperman index and the Menopause Symptom Checklist, that were derived from the clinical experiences of women living ...
New software tool identifies genetic mutations that influence disease risk
2014-05-30
HOUSTON-Researchers at The University of Texas MD Anderson Cancer Center and other institutions have applied a newly developed software tool to identify genetic mutations that contribute to a person's increased risk for developing common, complex diseases, such as cancer. The research is published in the May 2014 edition of the journal Nature Biotechnology.
The technology, known as pVAAST (pedigree Variant Annotation, Analysis and Search Tool), combines two different statistical methods used for identifying disease-causing gene mutations. This combination approach outperforms ...
Study links urbanization and future heat-related mortality
2014-05-30
TEMPE, Ariz. – Phoenix stands at a parched crossroads. Global scale climate change is forecast to bring hotter summers and more extreme heat to the Valley, but regional urbanization also will impact temperatures experienced by residents.
So how should Phoenix grow knowing that such growth could cause temperatures to increase in the future and bring added health risks? Should the city deploy mitigating technologies to help fight summer's heat? Would adopting a low-growth strategy reduce the adverse health consequences of hot weather?
New Arizona State University research ...
DNA-binding fluorescent dyes detect real-time cell toxicity during drug screening
2014-05-30
New Rochelle, NY, May 30, 2014—High throughput screening of compounds in live cells is a powerful approach for discovering new drugs, but the potential for cell toxicity must be considered. A novel technique that uses DNA-binding fluorescent dyes to evaluate the cytotoxicity of an experimental compound in real-time during screening, saving time and resources, is described in ASSAY and Drug Development Technologies, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the ASSAY and Drug Development Technologies website.
Lucius Chiaraviglio ...
Study explains how green tea could reduce pancreatic cancer risk
2014-05-30
LOS ANGELES – (May 30, 2014) – Green tea and its extracts have been widely touted as potential treatments for cancer, as well as several other diseases. But scientists have struggled to explain how the green tea and its extracts may work to reduce the risk of cancer or to slow the growth of cancer cells.
A study recently published online by the journal, Metabolomics, offers an explanation that researchers say could open a new area of cancer-fighting research. The study reports that EGCG, the active biologic constituent in green tea, changed the metabolism of pancreatic ...